HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

pf-06763809

RORC2 inverse agonist

Networked: 1 relevant articles (1 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 133
- pf-06763809: 1

Experts

1.	Banfield, C: 1 article (01/2021)
2.	Beaumont, K: 1 article (01/2021)
3.	Berger, Z: 1 article (01/2021)
4.	Berstein, G: 1 article (01/2021)
5.	Dowty, H: 1 article (01/2021)
6.	Garcet, S: 1 article (01/2021)
7.	Hamscho, R: 1 article (01/2021)
8.	Kieras, E: 1 article (01/2021)
9.	Kroencke, U: 1 article (01/2021)
10.	Krueger, J G: 1 article (01/2021)

Related Diseases

1.

Psoriasis (Pustulosis Palmaris et Plantaris)

01/01/2021 - "A phase I, randomized, double-blind study to assess the safety, tolerability and efficacy of the topical RORC2 inverse agonist PF-06763809 in participants with mild-to-moderate plaque psoriasis."
01/01/2021 - "To assess the safety, tolerability and effect on skin infiltrate thickness of PF-06763809 in participants with mild/moderate chronic plaque psoriasis. "
01/01/2021 - "Using a psoriasis plaque test design, PF-06763809 was found to be well tolerated with an acceptable safety profile in participants with psoriasis, but without reduction in skin infiltrate thickness or disease biomarkers."
01/01/2021 - "The RORC2 inhibitor PF-06763809 has been hypothesized to inhibit IL-17A production in T-helper 17 (Th17) cells, thereby reducing psoriasis symptoms. "

Related Drugs and Biologics

1.	Interleukin-17 (Interleukin 17)
2.	Biomarkers (Surrogate Marker)